Open AccessNormal human immunoglobulins for intravenous use (IVIg) delay hyperacute xenograft rejection through F(ab')2-mediated anti-complement activity
Author(s) -
C. Latrémouille,
D. Genevaz,
Ming C Hu,
Olivier Schussler,
Nathalie Goussef,
Chantal Mandet,
Patrick Bruneval,
Nicole HaeffnerCavaillon,
A Carpentier,
Denis Glotz
Publication year - 1997
Publication title -
clinical and experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1046/j.1365-2249.1997.4591358.x
Subject(s) - xenotransplantation , antibody , immunology , polyclonal antibodies , complement system , medicine , intravenous immunoglobulins , guinea pig , transplantation
Xenotransplantation between discordant species leads to a hyperacute rejection mediated by natural antibodies, both of the IgG and IgM isotypes, activation of complement and endothelial cell activation. The combination of these mechanisms leads to a transplant survival of minutes to a few hours. Polyclonal human immunoglobulins for intravenous use (IVIg) from normal donors have proved effective in a number of antibody-mediated disorders, as well as in inflammatory disorders. We demonstrate that administration of IVIg in a guinea pig to rat model of cardiac xenografting can effectively delay hyperacute rejection. This effect is mediated by the F(ab')2 fragments of IVIg, and is correlated to an anti-complementary activity.